KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Dividends Paid - Common (2019 - 2025)

Historic Dividends Paid - Common for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $40.8 million.

  • Royalty Pharma's Dividends Paid - Common rose 2959.81% to $40.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $167.5 million, marking a year-over-year increase of 3380.98%. This contributed to the annual value of $167.5 million for FY2025, which is 3380.98% up from last year.
  • Royalty Pharma's Dividends Paid - Common amounted to $40.8 million in Q4 2025, which was up 2959.81% from $34.3 million recorded in Q3 2025.
  • Royalty Pharma's 5-year Dividends Paid - Common high stood at $125.7 million for Q1 2021, and its period low was -$230.2 million during Q4 2021.
  • For the 5-year period, Royalty Pharma's Dividends Paid - Common averaged around $34.5 million, with its median value being $33.8 million (2023).
  • Data for Royalty Pharma's Dividends Paid - Common shows a peak YoY increase of 11440.15% (in 2022) and a maximum YoY decrease of 7254.64% (in 2022) over the last 5 years.
  • Over the past 5 years, Royalty Pharma's Dividends Paid - Common (Quarter) stood at -$230.2 million in 2021, then skyrocketed by 114.4% to $33.2 million in 2022, then fell by 26.13% to $24.5 million in 2023, then increased by 28.42% to $31.4 million in 2024, then increased by 29.6% to $40.8 million in 2025.
  • Its last three reported values are $40.8 million in Q4 2025, $34.3 million for Q3 2025, and $38.6 million during Q2 2025.